Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · refreshes every 15s during session
Seaport Therapeutics, Inc. execution reads as mixed on proprietary earnings and initiative evidence.
Why it matters: New data from Phase 1 trial of GlyphAgoTM (Q2 FY2026).
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
SPTX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on SPTX.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Seaport Therapeutics, Inc. (SPTX) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
SPTX's AI investment thesis
Upgrade to Premium for SPTX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Latest price
$21.52
Market cap
$1.15B
Profitable
—
Net income
—
FY Sep 5, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Seaport Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Seaport Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.